

New Italian study shows that K.O.S has positive effects on allergic rhinitis

The results of the new investigator-initiated study titled "Effectiveness of Kinetic Oscillation Stimulation Treatment in Persistent Moderate-Severe Allergic Rhinitis Compared to Medical Therapy" demonstrate that Chordate's K.O.S treatment improves nasal airflow more effectively than medical therapy alone in cases of persistent moderate to severe allergic rhinitis. Symptoms such as congestion, runny nose, itching, and sneezing significantly decreased in patients who received medical treatment in combination with K.O.S.

"We have not previously investigated the effects with K.O.S on allergic rhinitis in particular, so these results are very positive and potentially open up new opportunities for the company," says Jan Hermansson, Chief Medical Officer of Chordate.

The patients in this study were diagnosed using skin prick tests on the arm or blood tests to confirm allergies, including allergies to dust mites, among others.

"This is important new information for physicians treating patients where allergens such as pollen and dust mites are frequently present. Patients with rhinitis often have a combination of allergic and non-allergic rhinitis, which may be a reason why a K.O.S-treatment combination provides the indicated improvement,"

The study was conducted by, among others, Dr. Lino Di Rienzo Businco, and was published in [Journal of Otolaryngology Research & Reports](#).

For more information, please contact:

Anders Weilandt, CEO

anders.weilandt@chordate.com

Cell: +46 733-874277

About Chordate

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked a neuromodulation and drug-free treatment technology for chronic migraine and chronic nasal congestion (rhinitis), Kinetic Oscillation Stimulation (K.O.S). The treatment has clinically proven efficacy according to a recent study, and is marketed in Finland, Germany, the UK, Italy, Israel, and Saudi Arabia. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Press Release
29 May 2023 09:25:00 CEST

CHORDATE
M E D I C A L

Attachments

[New Italian study shows that K.O.S has positive effects on allergic rhinitis](#)